JP2016539180A5 - - Google Patents

Download PDF

Info

Publication number
JP2016539180A5
JP2016539180A5 JP2016547985A JP2016547985A JP2016539180A5 JP 2016539180 A5 JP2016539180 A5 JP 2016539180A5 JP 2016547985 A JP2016547985 A JP 2016547985A JP 2016547985 A JP2016547985 A JP 2016547985A JP 2016539180 A5 JP2016539180 A5 JP 2016539180A5
Authority
JP
Japan
Prior art keywords
phenyl
group
benzothiazole
enantiomer
enantiomers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016547985A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016539180A (ja
JP6463366B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/060174 external-priority patent/WO2015054662A1/en
Publication of JP2016539180A publication Critical patent/JP2016539180A/ja
Publication of JP2016539180A5 publication Critical patent/JP2016539180A5/ja
Application granted granted Critical
Publication of JP6463366B2 publication Critical patent/JP6463366B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016547985A 2013-10-10 2014-10-10 １２−リポキシゲナーゼ阻害物質としての４−（（２−ヒドロキシ−３−メトキシベンジル）アミノ）ベンゼンスルホンアミド誘導体 Active JP6463366B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361889396P 2013-10-10 2013-10-10
US61/889,396 2013-10-10
US201461987129P 2014-05-01 2014-05-01
US61/987,129 2014-05-01
PCT/US2014/060174 WO2015054662A1 (en) 2013-10-10 2014-10-10 4-((2-hydroxy-3-methoxybenzyl)amino) benzenesulfonamide derivatives as 12-lipoxygenase inhibitors

Publications (3)

Publication Number Publication Date
JP2016539180A JP2016539180A (ja) 2016-12-15
JP2016539180A5 true JP2016539180A5 (enExample) 2018-04-26
JP6463366B2 JP6463366B2 (ja) 2019-01-30

Family

ID=52813691

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016547985A Active JP6463366B2 (ja) 2013-10-10 2014-10-10 １２−リポキシゲナーゼ阻害物質としての４−（（２−ヒドロキシ−３−メトキシベンジル）アミノ）ベンゼンスルホンアミド誘導体

Country Status (7)

Country Link
US (3) US10266488B2 (enExample)
EP (1) EP3054936B1 (enExample)
JP (1) JP6463366B2 (enExample)
CA (1) CA2926950C (enExample)
DK (1) DK3054936T5 (enExample)
ES (1) ES2968371T3 (enExample)
WO (1) WO2015054662A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2968371T3 (es) 2013-10-10 2024-05-09 Eastern Virginia Medical School Derivados de 4-((2-hidroxi-3-metoxibencil)amino) bencenosulfonamida como inhibidores de la 12-lipoxigenasa
GB201419579D0 (en) * 2014-11-03 2014-12-17 Iomet Pharma Ltd Pharmaceutical compound
EP3475442B1 (en) * 2016-06-23 2024-10-23 The Regents of The University of Michigan 12(s)-hydroxyeicosatrienoic acid compounds and their use as therapeutic agents
RU2665411C1 (ru) * 2017-03-30 2018-08-29 Александр Александрович Кролевец Способ получения нанокапсул стрептоцида в ксантановой камеди
CN107441100B (zh) * 2017-08-21 2020-08-28 武汉惠康达科技有限公司 治疗缺血再灌注损伤的化合物
CN109694395B (zh) * 2017-10-23 2020-08-28 武汉惠康达科技有限公司 一种用于缺血再灌注损伤的化合物及其制备方法
WO2019204375A1 (en) * 2018-04-17 2019-10-24 The Regents Of The University Of Michigan Selective inhibitors of 12(s)-lipoxygenase (12-lox) and methods for use of the same
AU2020289560A1 (en) 2019-06-05 2021-12-23 Emory University Peptidomimetics for the treatment of coronavirus and picornavirus infections
CN110256305B (zh) * 2019-07-24 2020-05-26 中国药科大学 一种萘磺酰胺类化合物、制备方法和应用
EP4081199A4 (en) * 2019-12-23 2024-01-17 SRI International LIPOXYGENASE INHIBITORS
CN111184864B (zh) * 2020-01-20 2022-01-14 武汉大学 Alox12特异性抑制剂在制备治疗非酒精性脂肪肝病和/或ⅱ型糖尿病的药物中的应用
EP4232060B1 (en) * 2020-10-20 2026-07-01 The Regents of the University of Michigan COMPOSITIONS AND METHODS OF TREATMENT OF CARDIOVASCULAR DISORDERS
US20220257614A1 (en) * 2021-02-16 2022-08-18 New York Medical College Use of 12-lipoxygenase inhibitors in the treatment of covid-19
US20240279190A1 (en) * 2021-05-07 2024-08-22 The Regents Of The University Of California Compounds for modulating platelet-type 12-(s)-lipoxygenase and methods of use for same
CN113861130A (zh) * 2021-09-29 2021-12-31 守恒(厦门)医疗科技有限公司 联苯磺胺噻二唑类衍生物及其在抗肿瘤药物的应用
CN113698357A (zh) * 2021-09-29 2021-11-26 守恒(厦门)医疗科技有限公司 磺胺嘧啶类衍生物及其在抗肿瘤药物的应用
CN116370407A (zh) * 2021-12-22 2023-07-04 维拉洛斯治疗公司 包含4-((2-羟基-3-甲氧基苯甲醇)氨基)苯磺酰胺衍生物的水性肠道外药物制剂
CA3242011A1 (en) * 2021-12-23 2023-06-29 David Maloney Compositions and methods of use to treat 12-lipoxygenase (12-lox) mediated diseases
WO2024019959A1 (en) * 2022-07-18 2024-01-25 The Regents Of The University Of California Compositions for modulating lipoxygenase and methods of using same
IL320544A (en) * 2022-11-02 2025-06-01 Veralox Therapeutics Inc Oral pharmaceutical formulations containing 4-((2-HYDROXY-3-METHOXYBENZYL)AMINO) BENZENE-SULPHONAMIDE DERIVATIVES
WO2024103023A2 (en) * 2022-11-11 2024-05-16 Veralox Therapeutics 12-lipoxygenase inhibitors for the treatment of lupus
CN122349426A (zh) * 2023-06-22 2026-07-07 卡德雷纳治疗公司 治疗12-脂氧合酶(12-lox)介导的疾病的组合物和使用方法
WO2025207887A1 (en) * 2024-03-27 2025-10-02 Veralox Therapeutics Inc. Methods for treating heparin-induced thrombocytopenia

Family Cites Families (174)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4089809A (en) 1976-03-01 1978-05-16 The United States Of America As Represented By The United States Department Of Energy Regenerable sorbent and method for removing hydrogen sulfide from hot gaseous mixtures
US4233871A (en) 1978-04-26 1980-11-18 Alessi Anthony A Notching tool
DE3068743D1 (en) 1980-01-16 1984-08-30 Weder Hans G Process and dialysis-installation for the preparation of bilayer-vesicles and their use
US4485054A (en) 1982-10-04 1984-11-27 Lipoderm Pharmaceuticals Limited Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV)
US4438253A (en) 1982-11-12 1984-03-20 American Cyanamid Company Poly(glycolic acid)/poly(alkylene glycol) block copolymers and method of manufacturing the same
JPS60100516A (ja) 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
US4532089A (en) 1984-01-14 1985-07-30 Northwestern University Method of preparing giant size liposomes
US4897269A (en) 1984-09-24 1990-01-30 Mezei Associates Limited Administration of drugs with multiphase liposomal delivery system
US4605669A (en) 1985-04-26 1986-08-12 Abbott Laboratories Lipoxygenase inhibiting naphthohydroxamic acids
US4623661A (en) 1985-04-26 1986-11-18 Abbott Laboratories Lipoxygenase inhibiting compounds
US4761403A (en) 1986-04-09 1988-08-02 Abbott Laboratories Lipoxygenase inhibiting compounds
ES2059408T3 (es) 1987-02-10 1994-11-16 Abbott Lab Un proceso para la preparacion de un compuesto.
US4897422A (en) 1987-02-10 1990-01-30 Abbott Laboratories Lipoxygenase inhibiting compounds
US5571821A (en) 1993-05-20 1996-11-05 Texas Biotechnology Corporation Sulfonamides and derivatives thereof that modulate the activity of endothelin
US4822811A (en) 1987-11-13 1989-04-18 Abbott Laboratories Carbazole lipoxygenase inhibiting compounds, compositions and use
CA1334975C (en) 1987-11-13 1995-03-28 James H. Holms Furan and pyrrole containing lipoxygenase inhibiting compounds
JP2670680B2 (ja) 1988-02-24 1997-10-29 株式会社ビーエムジー 生理活性物質含有ポリ乳酸系微小球およびその製造法
CA2046872A1 (en) 1989-02-01 1990-08-02 Dee W. Brooks Lipoxygenase inhibiting compounds
WO1990012008A1 (en) 1989-03-30 1990-10-18 Abbott Laboratories Urea based lipoxygenase inhibiting compounds
IL95584A (en) 1989-09-07 1995-03-15 Abbott Lab Indole-, benzoporene- and benzothiophene compounds including lipoxygenase-inhibiting compounds and pharmaceutical compounds containing them
US5580575A (en) 1989-12-22 1996-12-03 Imarx Pharmaceutical Corp. Therapeutic drug delivery systems
US5120752A (en) 1989-12-28 1992-06-09 Abbott Laboratories Cyclopropyl derivative lipoxygenase inhibitors
DE69425210T2 (de) 1993-04-13 2001-03-01 Morinaga Milk Industry Co. Ltd., Tokio/Tokyo Cumarin derivate und deren anwendung
DK77393D0 (da) 1993-06-29 1993-06-29 Novo Nordisk As Aktivering af enzymer
AU3577995A (en) 1994-10-04 1996-04-26 Fujisawa Pharmaceutical Co., Ltd. Urea derivatives and their use as acat-inhibitors
BR9507579A (pt) 1994-10-25 1997-09-09 Watson Clinic Foundation Processo fluorométrico para medir ativaçao de plaqueta endógena em amostra de plaquetas
US5710171A (en) 1995-05-24 1998-01-20 Merck & Co., Inc. Bisphenyl inhibitors of farnesyl-protein transferase
US5820880A (en) 1995-06-07 1998-10-13 The United States Of America As Represented By The Secretary Of The Army Liposomal formulation
WO1997001275A1 (en) 1995-06-29 1997-01-16 Merck & Co., Inc. Combinations of inhibitors of farnesyl-protein transferase
US5665428A (en) 1995-10-25 1997-09-09 Macromed, Inc. Preparation of peptide containing biodegradable microspheres by melt process
US5919792A (en) 1996-10-30 1999-07-06 Merck & Co., Inc. Integrin antagonists
JP2001504456A (ja) 1996-10-30 2001-04-03 メルク エンド カンパニー インコーポレーテッド インテグリン拮抗薬
CA2268916A1 (en) 1996-10-30 1998-05-07 Merck & Co., Inc. Integrin antagonists
DE19740785A1 (de) 1997-02-21 1998-08-27 Bayer Ag Arylsulfonamide und Analoga
CA2470183C (en) 1997-02-21 2008-01-29 Bayer Aktiengesellschaft Intermediates for preparing arylsulphonamides and analogues
GB9703756D0 (en) 1997-02-24 1997-04-16 British Steel Plc Composite structures
JP4231559B2 (ja) 1997-04-23 2009-03-04 オリザ油化株式会社 リポキシゲナーゼ阻害剤
US6140351A (en) 1997-12-19 2000-10-31 Berlex Laboratories, Inc. Ortho-anthranilamide derivatives as anti-coagulants
NZ503809A (en) 1997-12-19 2002-04-26 Schering Ag Ortho-anthranilamide derivatives as anti-coagulants
CA2321142A1 (en) * 1998-02-27 1999-09-02 Regents Of The University Of California Protease-activated receptor 4 and uses thereof
ZA992029B (en) 1998-03-12 1999-09-27 Novo Nordisk As Modulators of protein tyrosine phosphates (PTYases).
US6225329B1 (en) 1998-03-12 2001-05-01 Novo Nordisk A/S Modulators of protein tyrosine phosphatases (PTPases)
WO1999046236A1 (en) 1998-03-12 1999-09-16 Novo Nordisk A/S Modulators of protein tyrosine phosphatases (ptpases)
US6391568B1 (en) 1998-07-15 2002-05-21 Lionheart Technologies, Inc. Method for determining platelet reactivity in a whole blood sample
US6586475B1 (en) 1998-11-20 2003-07-01 Takeda Chemical Industries, Ltd. β-amyloid protein production/secretion inhibitors
JP2000212076A (ja) 1998-11-20 2000-08-02 Takeda Chem Ind Ltd βアミロイド蛋白産生・分泌阻害剤
US6287588B1 (en) 1999-04-29 2001-09-11 Macromed, Inc. Agent delivering system comprised of microparticle and biodegradable gel with an improved releasing profile and methods of use thereof
WO2000067776A1 (en) 1999-05-11 2000-11-16 Ortho-Mcneil Pharmaceuticals, Inc. Pharmacokinetic and pharmacodynamic modeling of erythropoietin administration
WO2001004159A1 (en) 1999-07-13 2001-01-18 Science & Technology Corporation @Unm Compositions and methods useful for the diagnosis and treatment of heparin induced thrombocytopenia/thrombosis
US6632815B2 (en) 1999-09-17 2003-10-14 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
US6720317B1 (en) 1999-09-17 2004-04-13 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
AU781880B2 (en) 1999-09-17 2005-06-16 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
US6844367B1 (en) 1999-09-17 2005-01-18 Millennium Pharmaceuticals, Inc. Benzamides and related inhibitors of factor Xa
TWI284639B (en) 2000-01-24 2007-08-01 Shionogi & Co A compound having thrombopoietin receptor agonistic effect
WO2001064642A2 (en) 2000-02-29 2001-09-07 Cor Therapeutics, Inc. Benzamides and related inhibitors of factor xa
AU6589801A (en) * 2000-04-28 2001-11-12 F. Hoffmann-La Roche Ag P-(sulfonyl)aryl and heteroaryls
GB0027309D0 (en) 2000-11-08 2000-12-27 Barts And The London Nat Healt Method of measuring measuring platlet activation
AU2002223492A1 (en) 2000-11-14 2002-05-27 Neurosearch A/S Use of malaria parasite anion channel blockers for treating malaria
AU2002225767A1 (en) 2000-11-28 2002-06-11 Guilford Pharmaceuticals Inc. Bisubstituted carbocyclic cyclophilin binding compounds and theirus
EP1217000A1 (en) 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibitors of factor Xa and factor VIIa
ES2200617B1 (es) 2001-01-19 2005-05-01 Almirall Prodesfarma, S.A. Derivados de urea como antagonistas de integrinas alfa 4.
US6670364B2 (en) 2001-01-31 2003-12-30 Telik, Inc. Antagonists of MCP-1 function and methods of use thereof
DE10105751B4 (de) 2001-02-08 2005-09-29 Oxeno Olefinchemie Gmbh Verfahren zur Herstellung von 1-Octen
DE10105754A1 (de) 2001-02-08 2002-08-14 Werner P Berwald Reibungsschloß aus Systemteilen mit Mehrfachfunktionen für eine offene Profilverbindung eines Gleitbogenausbaus aus gewalzten Rinnenprofilen
AU2002317377A1 (en) 2001-07-20 2003-03-03 Cancer Research Technology Limited Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer
FI116940B (fi) * 2001-07-20 2006-04-13 Juvantia Pharma Ltd Oy Alfa-2B-adrenoseptorivälitteisen sairauden hoitoon tai ehkäisyyn käyttökelpoiset yhdisteet
SE0102716D0 (sv) 2001-08-14 2001-08-14 Astrazeneca Ab Novel compounds
AUPR738301A0 (en) 2001-08-30 2001-09-20 Starpharma Limited Chemotherapeutic agents
JP2005509028A (ja) 2001-10-09 2005-04-07 バーテックス ファーマシューティカルズ インコーポレイテッド アスパラギン酸およびグルタミン酸誘導体ならびにそのジアゾケトン中間体を合成するための方法
EP1463505A2 (en) 2001-12-13 2004-10-06 Abbott Laboratories 3-(phenyl-alkoxy)-5-(phenyl)-pyridine derivatives and related compounds as kinase inhibitors for the treatment of cancer
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
TWI320409B (en) 2002-01-18 2010-02-11 Almirall Lab Urea derivatives as integrin 4 antagonists
AU2003249369A1 (en) 2002-06-21 2004-01-06 Cellular Genomics, Inc. Certain amino-substituted monocycles as kinase modulators
CN101130526B (zh) 2002-06-27 2013-07-10 诺沃挪第克公司 用作治疗剂的芳基羰基衍生物
KR101124245B1 (ko) 2002-06-27 2012-07-02 노보 노르디스크 에이/에스 치료제로서 아릴 카르보닐 유도체
CA2744893A1 (en) 2002-06-27 2004-01-08 Novo Nordisk A/S Aryl carbonyl derivatives as glucokinase activators
JP2006512306A (ja) 2002-08-29 2006-04-13 テンプル・ユニバーシティ−オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイション アリール及びヘテロアリールプロペンアミド、それらの誘導体並びにそれらの治療用途
CA2512000C (en) 2002-12-26 2011-08-09 Eisai Co., Ltd. Selective estrogen receptor modulator
DE10300097A1 (de) 2003-01-07 2004-07-22 Bayer Ag Kupfer-Komplexe und ihre Verwendung
DE10300098A1 (de) 2003-01-07 2004-07-15 Bayer Ag Kupfer-Carben-Komplexe und ihre Verwendung
US7320989B2 (en) 2003-02-28 2008-01-22 Encysive Pharmaceuticals, Inc. Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists
JP2006519258A (ja) 2003-02-28 2006-08-24 エンサイシブ・ファーマシューティカルズ・インコーポレイテッド ピリジン、ピリミジン、キノリン、キナゾリンおよびナフタレン系のウロテンシン−ｉｉ受容体拮抗薬
TW200505902A (en) 2003-03-20 2005-02-16 Schering Corp Cannabinoid receptor ligands
WO2004099127A1 (en) 2003-05-07 2004-11-18 Novo Nordisk A/S Novel compounds as kinase inhibitors
US7375126B2 (en) 2003-06-12 2008-05-20 Abbott Laboratories Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
AU2011244937A1 (en) 2003-06-12 2011-11-24 Abbott Laboratories Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
US7015233B2 (en) 2003-06-12 2006-03-21 Abbott Laboratories Fused compounds that inhibit vanilloid subtype 1 (VR1) receptor
AR044694A1 (es) 2003-06-17 2005-09-21 Schering Corp Proceso y compuestos intermedios para la preparacion de (1r, 2s,5s) - 3 azabiciclo [3,1,0] hexano-2- carboxamida, n- [3- amino-1- (ciclobutilmetil) - 2, 3 - dioxopropil] -3- [ (2s) - 2 - [[ [ 1,1- dimetiletil] amino] carbonilamino] -3,3-dimetil -1- oxobutil]-6,6 dimetilo
WO2005000309A2 (en) 2003-06-27 2005-01-06 Ionix Pharmaceuticals Limited Chemical compounds
JPWO2005012221A1 (ja) 2003-08-04 2006-09-14 小野薬品工業株式会社 ジフェニルエーテル化合物、その製造方法および用途
WO2005065074A2 (en) 2003-09-09 2005-07-21 Temple University Of The Commonwealth System Of Higher Education Protection of tissues and cells from cytotoxic effects of ionizing radiation by abl inhibitors
CN1878769A (zh) 2003-09-11 2006-12-13 凯米亚公司 细胞因子抑制剂
SG146624A1 (en) 2003-09-11 2008-10-30 Kemia Inc Cytokine inhibitors
GB0321710D0 (en) 2003-09-16 2003-10-15 Novartis Ag Organic compounds
WO2005037223A2 (en) 2003-10-15 2005-04-28 Brigham And Women's Hospital, Inc. Methods and compositions for immunomodulation
GB0328243D0 (en) 2003-12-05 2004-01-07 Astrazeneca Ab Methods
CN1660811A (zh) 2004-02-27 2005-08-31 中国科学院上海药物研究所 1，4－二取代苯类化合物及其制备方法和用途
CA2555914A1 (en) 2004-03-08 2005-09-22 Amgen Inc. Therapeutic modulation of ppar (gamma) activity
KR100541110B1 (ko) 2004-06-25 2006-01-11 삼성전기주식회사 다파장 반도체 레이저 제조방법
US7671077B2 (en) 2004-07-19 2010-03-02 Leu-Fen Hou Lin Neuroprotective small organic molecules, compositions and uses related thereto
WO2006038594A1 (ja) 2004-10-04 2006-04-13 Ono Pharmaceutical Co., Ltd. Ｎ型カルシウムチャネル阻害薬
US20060074103A1 (en) 2004-10-06 2006-04-06 Corte James R Cyclic beta-amino acid derivatives as factor Xa inhibitors
DE102004051277A1 (de) 2004-10-21 2006-04-27 Merck Patent Gmbh Heterocyclische Carbonylverbindungen
WO2006078941A2 (en) 2005-01-20 2006-07-27 Sirtris Pharmaceuticals, Inc. Novel sirtuin activating compounds and methods of use thereof
AU2005328327A1 (en) 2005-02-25 2006-09-08 Galileo Pharmaceuticals, Inc. Novel lipoxygenase inhibitors
WO2006138418A2 (en) 2005-06-14 2006-12-28 President And Fellows Of Harvard College Improvement of cognitive performance with sirtuin activators
CN100343236C (zh) 2005-09-02 2007-10-17 中国科学院上海有机化学研究所 [n－(2－嘧啶氧基)苄氨基苯基]磺酰胺类化合物、制备方法及其用途
KR20080058436A (ko) 2005-10-13 2008-06-25 와이어쓰 글루탐산 유도체의 제조 방법
US20090176776A1 (en) 2005-10-21 2009-07-09 University Of Alabama At Birmingham Small molecule inhibitors of hiv-1 capsid assembly
GB0522061D0 (en) 2005-10-28 2005-12-07 Glaxo Group Ltd Chemical process
US20070111965A1 (en) 2005-11-15 2007-05-17 Kipp James E Compositions comprising lipoxygenase inhibitors and cyclodextrin
GB0526240D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
EP1996732A4 (en) 2006-03-02 2010-03-31 Uab Research Foundation RECOGNITION AND TREATMENT AND DISCOVERY OF REMEDIES AGAINST MYCOBACTERIAL DISEASES
AU2013254904A1 (en) 2006-03-02 2014-02-20 The Uab Research Foundation Mycobacterial disease detection, treatment, and drug discovery
GB0606283D0 (en) 2006-03-29 2006-05-10 Cyclacel Ltd Process
US8129357B2 (en) 2006-04-07 2012-03-06 Academia Sinica Method of making and using an adenosine analogue
US7351434B2 (en) 2006-04-07 2008-04-01 Academia Sinica Therapeutic Gastrodia extracts
CA2656067C (en) 2006-06-23 2014-08-12 Radius Health, Inc. Treatment of vasomotor symptoms with selective estrogen receptor modulators
US20080227799A1 (en) 2006-07-11 2008-09-18 Liotta Dennis C CXCR4 Antagonists Including Heteroatoms for the Treatment of Medical Disorders
PT2101760E (pt) 2006-12-08 2013-05-07 Millennium Pharm Inc Formulações de dose unitária e métodos de tratamento da trombose com um inibidor oral do fator xa
CN101652136A (zh) 2006-12-08 2010-02-17 米伦纽姆医药公司 使用经口因子xa抑制剂治疗血栓形成的单位剂量调配物和方法
WO2008072341A1 (ja) 2006-12-15 2008-06-19 Pioneer Corporation 描画装置及び方法、並びにコンピュータプログラム
WO2008089307A2 (en) 2007-01-18 2008-07-24 Lexicon Pharmaceuticals, Inc. Delta 5 desaturase inhibitors for the treatment of pain, inflammation and cancer
US20080200458A1 (en) 2007-01-18 2008-08-21 Joseph Barbosa Methods and compositions for the treatment of body composition disorders
WO2008103276A2 (en) 2007-02-16 2008-08-28 Merck & Co., Inc. Compositions and methods for potentiated activity of biologicaly active molecules
WO2008104994A2 (en) 2007-02-28 2008-09-04 Advinus Therapeutics Private Limited 2,2,2-tri-substituted acetamide derivatives as glucokinase activators, their process and pharmaceutical application
WO2008112156A1 (en) 2007-03-08 2008-09-18 Altiris Therapeutics Chemokine receptor modulators
US20080261978A1 (en) 2007-03-08 2008-10-23 Clark Michael P Chemokine receptor modulators
US7928111B2 (en) 2007-06-08 2011-04-19 Senomyx, Inc. Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors
US8633186B2 (en) 2007-06-08 2014-01-21 Senomyx Inc. Modulation of chemosensory receptors and ligands associated therewith
AU2013202912B2 (en) 2007-06-08 2016-10-27 Firmenich Incorporated Modulation of chemosensory receptors and ligands associated therewith
US9603848B2 (en) 2007-06-08 2017-03-28 Senomyx, Inc. Modulation of chemosensory receptors and ligands associated therewith
JP5460589B2 (ja) 2007-07-13 2014-04-02 アイカジェン， インコーポレイテッド ナトリウムチャネル阻害物質
HUE025137T2 (en) 2007-08-21 2016-01-28 Senomyx Inc Compositions are bitter taste blocking (blocking) compounds
AU2008345225A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
JP2009209090A (ja) 2008-03-04 2009-09-17 Mitsui Chemicals Inc 殺虫剤及び該殺虫剤に含まれる化合物、並びに該化合物の使用方法
CL2009000600A1 (es) 2008-03-20 2010-05-07 Bayer Cropscience Ag Uso de compuestos de diaminopirimidina como agentes fitosanitarios; compuestos de diaminopirimidina; su procedimiento de preparacion; agente que los contiene; procedimiento para la preparacion de dicho agente; y procedimiento para combatir plagas de animales y/u hongos dañinos patogenos de plantas.
WO2009118596A2 (en) 2008-03-26 2009-10-01 Glenmark Pharmaceuticals, S. A. Phthalimide derivatives as trpa1 modulators
EP2291349A2 (en) 2008-04-14 2011-03-09 The Board of Regents of The University of Texas System Small molecule inhibitors of the pleckstrin homology domain and methods for using same
GB0810011D0 (en) * 2008-06-02 2008-07-09 Jackson William P 5-Lipoxygenase inhibitors
US20110294853A1 (en) 2008-09-12 2011-12-01 Benjamin Pelcman Bis Aromatic Compounds for Use in the Treatment of Inflammation
CN101759683B (zh) 2008-12-25 2011-12-28 哈尔滨誉衡药业股份有限公司 二氢化茚酰胺化合物制备方法、包含其的药物组合物、及其作为蛋白激酶抑制剂的应用
WO2010123139A1 (ja) 2009-04-24 2010-10-28 持田製薬株式会社 スルファモイル基を有するアリールカルボキサミド誘導体
ES2749504T3 (es) 2009-10-13 2020-03-20 Ligand Pharm Inc Compuestos de moléculas pequeñas miméticos del factor de crecimiento hematopoyético y sus usos
WO2011070444A2 (en) 2009-12-07 2011-06-16 Roberto Testi Compositions and methods for treating friedreich's ataxia
US20130022629A1 (en) 2010-01-04 2013-01-24 Sharpe Arlene H Modulators of Immunoinhibitory Receptor PD-1, and Methods of Use Thereof
US20130131140A1 (en) * 2010-01-14 2013-05-23 Jerry L. Nadler Treatment of diabetes and disorders associated with visceral obesity with inhibitors of human arachidonate 12 lipoxygenase and arachidonate 15-lipoxygenase
CN102206172B (zh) 2010-03-30 2015-02-25 中国医学科学院医药生物技术研究所 一组取代双芳基化合物及其制备方法和抗病毒应用
EP2560636A4 (en) 2010-04-23 2013-11-27 Kineta Inc ANTIVIRAL CONNECTIONS
WO2011146618A1 (en) 2010-05-18 2011-11-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inhibitors of human 12-lipoxygenase
WO2011155898A1 (en) 2010-06-11 2011-12-15 Wadell Goeran New antiviral compounds
WO2012016133A2 (en) 2010-07-29 2012-02-02 President And Fellows Of Harvard College Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers
WO2012021401A1 (en) 2010-08-12 2012-02-16 Novozymes, Inc. Compositions comprising a polypeptide having cellulolytic enhancing activity and a bicyclic compound and uses thereof
WO2012068406A2 (en) 2010-11-18 2012-05-24 Ligand Pharmaceuticals Incorporated Use of hematopoietic growth factor mimetics
WO2012068589A2 (en) 2010-11-19 2012-05-24 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
USRE47009E1 (en) 2011-02-01 2018-08-28 The Children's Hospital Of Philadelphia HDAC inhibitors and therapeutic methods using the same
US20130338369A1 (en) 2011-03-07 2013-12-19 Basf Se Process for the Synthesis of Aminobiphenylene
EP2546229A1 (de) 2011-07-15 2013-01-16 Friedrich-Alexander-Universität Erlangen-Nürnberg Verfahren zur Synthese von Aminobiphenylen
WO2012129562A2 (en) 2011-03-24 2012-09-27 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
JP6007417B2 (ja) 2011-05-31 2016-10-12 レセプトス エルエルシー 新規ｇｌｐ−１受容体安定剤および調節剤
DK2753605T3 (da) 2011-09-09 2019-06-17 Lantheus Medical Imaging Inc Sammensætninger, fremgangsmåder, og systemer til syntesen og anvendelsen af billeddannelsesmidler
WO2013050441A1 (en) * 2011-10-05 2013-04-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for inhibiting or preventing platelet aggregation
CN104220417B (zh) 2012-03-07 2017-10-13 巴斯夫欧洲公司 使用芳基肼合成氨基联苯类的方法
WO2013165969A2 (en) 2012-05-01 2013-11-07 The Trustees Of The University Of Pennsylvania Methods and kits for diagnosing heparin-induced thrombocytopenia
CN104364751A (zh) 2012-06-08 2015-02-18 Nec卡西欧移动通信株式会社 电子设备及其控制方法和程序
ES2660287T3 (es) 2012-08-06 2018-03-21 Biogen Ma Inc. Compuestos que son agentes moduladores de s1p y/o agentes moduladores de atx
US9115122B2 (en) 2012-12-20 2015-08-25 University Of Maryland, Baltimore Non-ATP dependent inhibitors of extracellular signal-regulated kinase (ERK)
WO2014144952A2 (en) 2013-03-15 2014-09-18 Peter Walter Modulators of the eif2alpha pathway
WO2015035325A1 (en) 2013-09-06 2015-03-12 The Regents Of University Of California Intermolecular c-h silylation of unactivated arenes
CA2924527C (en) 2013-09-20 2022-07-12 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Compounds for treating prostate cancer
ES2968371T3 (es) 2013-10-10 2024-05-09 Eastern Virginia Medical School Derivados de 4-((2-hidroxi-3-metoxibencil)amino) bencenosulfonamida como inhibidores de la 12-lipoxigenasa
CN104163794A (zh) 2013-10-17 2014-11-26 中国药科大学 2-氨基芳环类血管内皮生长因子受体(vegfr)抑制剂及其制备方法和用途
JP2017508798A (ja) 2014-03-07 2017-03-30 ザ ジョンズ ホプキンス ユニバーシティ ヒストンリジン特異的デメチラーゼ（ｌｓｄ１）およびヒストンデアセチラーゼ（ｈｄａｃ）の阻害剤

Similar Documents

Publication Publication Date Title
ZA200604724B (en) Methods for suppressing an immune response or treating a proliferative disorder
JP2014513110A5 (enExample)
JP2019524883A5 (enExample)
JP2010524899A5 (enExample)
JP2014508811A5 (enExample)
JP6579103B2 (ja) ハロゲン置換へテロ環化合物の塩
JP2017502940A5 (enExample)
EA201591291A1 (ru) Производные пиримидона и их применение в лечении, облегчении или профилактике вирусного заболевания
JP2013525458A5 (enExample)
JP2019505594A5 (enExample)
RU2018131775A (ru) 6-арил-4-морфолин-1-илпиридоны, пригодные для лечения рака или диабета
JP2010524896A5 (enExample)
JP2015531774A5 (enExample)
JP2017538689A5 (enExample)
JOP20210039A1 (ar) مركبات بيريدين 6،2 - ديامينو
IL311873A (en) Combination therapy for treating malignancies
JP2010522770A5 (enExample)
JP2017507175A5 (enExample)
JP2017536342A5 (enExample)
RU2012130929A (ru) Гетероциклические соединения в качестве ингибиторов янус-киназы
JP2020503302A5 (enExample)
JP2016532647A5 (enExample)
BR112015016184A2 (pt) derivados de piridona e seu uso no tratamento, melhora ou prevenção de uma doença viral
RU2015150614A (ru) Новые 3, 4-дигидро-2н-изохинолин-1-оны и 2, 3-дигидро-изоиндол-1-оны
JP2016512243A5 (enExample)